GET DAILY SIGNALSKura Oncology (KURA) and Syndax (SNDX): Comparing Two Menin Inhibitor Biotechs in AML
Key Takeaways
- Both KURA and SNDX focus on oncology and are bringing menin inhibitors to market for acute myeloid leukemia (AML), though they differ in how far along they are commercially.
- SNDX reported roughly $172 million in full-year 2025 revenue from its two approved products, while KURA is just starting to generate sales from its initial launch.
- KURA holds a larger cash position of about $667 million compared with SNDX at roughly $394 million, which supports its development runway but also reflects its earlier revenue stage.
- Wall Street analysts generally remain positive on both stocks, with average price targets sitting well above recent trading levels.
- Tickeron AI Verdict: Drawing from observable factors such as commercial traction, broader approved indications, and revenue momentum, the AI currently favors SNDX over KURA.
- For updates on catalysts and daily price action, check KURA Major News, KURA Today's Price Move, SNDX Major News, and SNDX Today's Price Move.
- To see how algorithmic strategies are positioned across thousands of tickers, explore Trending AI Robots.
Setting the Context for These Two Oncology Names
Kura Oncology (KURA) and Syndax Pharmaceuticals (SNDX) are both moving from clinical development into the commercial phase with menin inhibitors aimed at genetically defined acute leukemias. Their lead programs target overlapping patient groups, which makes their relative progress a useful comparison for investors focused on small-cap biotech names that share similar catalysts but sit at different points in their commercial journeys.
Kura Oncology’s Position and Recent Activity
Kura Oncology’s lead asset, KOMZIFTI (ziftomenib), received approval for relapsed or refractory AML with a susceptible NPM1 mutation. The company has now entered the commercial stage, with initial product sales and milestone payments from its partnership with Kyowa Kirin. Shares have traded in a relatively narrow range lately, and analyst targets point to meaningful upside from current levels. Early launch metrics include modest product revenue, solid payer coverage, and inclusion in NCCN guidelines. The company closed its most recent period with roughly $667 million in cash, giving it room to expand into solid tumors and combination regimens. Higher R&D and selling costs tied to the launch have kept the company unprofitable on a GAAP basis for now. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Syndax Pharmaceuticals’ Position and Recent Activity
Syndax has two approved products on the market. Revuforj (revumenib) targets KMT2A-rearranged and NPM1-mutant acute leukemias, while Niktimvo (axatilimab-csfr) addresses chronic graft-versus-host disease. The company posted full-year 2025 revenue of approximately $172 million, supported by both products and collaboration revenue, along with double-digit prescription growth. An expanded approval for Revuforj in NPM1-mutated AML widened its market. Cash stood at about $394 million at the end of the latest period. The business continues to post operating losses as it invests in commercialization and pipeline work. Analysts have kept mostly constructive ratings, with some adjustments after recent safety-label updates. When reviewing relative strength, I often glance at Tickeron’s AI Daily Buy/Sell Signals for a quick read on momentum.
Trending AI Robots
Tickeron’s Trending AI Robots page highlights the platform’s AI trading bots that monitor and trade across thousands of tickers. Rather than listing every strategy, it surfaces those best aligned with current market conditions. The bots cover a range of styles, timeframes, and performance metrics, allowing users to filter for approaches that fit their goals. For anyone looking at names like KURA and SNDX, the page can provide a data-driven view of how algorithmic models are interpreting momentum and positioning.
Head-to-Head Comparison
The main difference comes down to commercial maturity. SNDX runs a dual-product franchise with recurring revenue, whereas KURA is only beginning to convert its first approval into product sales. On the other side, KURA maintains a larger cash buffer that supports pipeline flexibility, while SNDX balances commercialization spending and losses on a smaller balance sheet. In label breadth, SNDX holds approvals across both KMT2A-rearranged and NPM1-mutant AML, giving it a wider reach than KURA’s NPM1-focused indication. Both companies face typical oncology biotech risks around regulation, clinical data, and competition, and both remain unprofitable under GAAP. Sentiment has stayed generally positive, though KURA carries more early-launch execution risk and SNDX must maintain prescription growth amid safety-label updates.
Tickeron AI Verdict
Considering trend consistency, stability, catalysts, and relative positioning, Tickeron’s AI currently points toward SNDX as the more favorable name. The read rests on its broader approved indications, established dual-product revenue base, and demonstrated top-line growth. KURA brings strengths of its own, including a larger cash position and the fresh commercial catalyst in KOMZIFTI, yet its earlier-stage revenue profile adds near-term execution uncertainty. This view reflects observable market positioning rather than a guarantee of future results.
Using Tickeron AI Tools in My Research
I regularly turn to Tickeron’s AI Trend Prediction Engine when comparing names like these, as it helps surface probabilistic signals based on historical patterns and current data. It keeps the analysis grounded without replacing my own review of fundamentals and catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
KURA's RSI Indicator ascending out of oversold territory
The RSI Indicator for KURA moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 30 of the 34 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where KURA advanced for three days, in 211 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
KURA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KURA as a result. In 69 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for KURA turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 36 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for KURA entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. KURA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.354) is normal, around the industry mean (3.498). P/E Ratio (-2.157) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (12.821) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical services
Industry Biotechnology
Advertisement